Safety of Apixaban for Cancer-Associated Thrombosis
- PMID: 33472252
- DOI: 10.1055/a-1367-7830
Safety of Apixaban for Cancer-Associated Thrombosis
Conflict of interest statement
B.B. reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to a specific type of IVC filters. D.J. has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; served as a speaker or a member of a speakers' bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, ROVI, and Sanofi; received grants for clinical research from Daiichi Sankyo, Sanofi, and ROVI.
Comment on
-
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.Thromb Haemost. 2021 May;121(5):616-624. doi: 10.1055/s-0040-1720975. Epub 2020 Nov 17. Thromb Haemost. 2021. PMID: 33202447 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
